Outlook Therapeutics (OTLK) Q3 FY26 earnings call

Outlook Therapeutics achieved a transformative milestone with the FDA approval of LYTENAVA for wet AMD, positioning the company for a significant U.S. commercial launch. The strategy focuses on leveraging bevacizumab's established use while navigating a competitive market with biosimilars and pricing pressures. The company is building out its commercial infrastructure and securing funding to support a measured, high-quality market entry, with a focus on market access and reimbursement, while also strategically assessing its European expansion.